The Onco Life Podcast

Breakthrough in Lung Cancer Treatment: Lurbinectedin and Atezolizumab Combo Extends Survival in ES-SCLC Patients

A new FDA-approved combination of lurbinectedin and atezolizumab is changing the outlook for patients with extensive-stage small cell lung cancer (ES-SCLC). This first-line maintenance therapy offers a major step forward in extending survival and disease control after initial treatment.

In this episode, you’ll learn:
 • How the lurbinectedin + atezolizumab combo improves survival and progression-free outcomes
 • Key findings from the IMforte Phase 3 clinical trial
 • What makes this treatment a new first-line maintenance option for ES-SCLC
 • Important safety and monitoring considerations for patients
 • Eligibility criteria and what it means for those in Malaysia
 • Why oncologists view this as a “practice-changing” advancement
 • How Onco Life Centre supports patients exploring new treatment options

This episode highlights a breakthrough that brings renewed hope to patients and families facing one of the most aggressive types of lung cancer.

Blog Link: Breakthrough in Lung Cancer: Lurbinectedin Combo Offers New Hope for ES-SCLC Patients

Send us a text

Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.

Author: Dr. CHRISTINA NG VAN TZE

📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.